Levels Pricing History and Trajectory: What You Actually Pay Over Time

What Levels Health Actually Is

Levels Health is a subscription-based metabolic health platform that pairs continuous glucose monitors (CGMs) with a proprietary mobile app. The app ingests real-time interstitial glucose readings and layers on food-logging, activity data, and a proprietary "metabolic score." The company does not manufacture CGM hardware. It acts as a facilitator between the user, a telehealth physician who writes the CGM prescription, and a pharmacy or distributor that ships Abbott FreeStyle Libre or Dexcom G7 sensors.

The CGM Technology Behind the Service

CGMs were originally developed and FDA-cleared for people with diabetes. The FDA's 510(k) database confirms clearances for the Abbott FreeStyle Libre 3 (K213767) and the Dexcom G7 as prescription devices for glucose management [1]. Levels repurposes these clinically validated sensors for a wellness population that is largely non-diabetic.

How Levels Differs From a Standard CGM Prescription

A person with type 2 diabetes can obtain a CGM through insurance with a physician's order. Levels operates outside that reimbursement pathway. Users pay retail sensor prices plus a software subscription, with no insurance processing. The FDA does not regulate Levels' metabolic scoring algorithm as a medical device, meaning the "Zone Score" the app generates carries no cleared diagnostic claim [2].

Continuous glucose monitoring in non-diabetic populations is an active research area. A 2023 analysis in the Journal of the Endocrine Society noted that CGM-derived metrics in metabolically healthy adults show wider physiologic variability than in people with diabetes, which limits the clinical interpretability of glucose "spikes" flagged by wellness apps [3].

Levels Pricing History: A Chronological Breakdown

2020 to Early 2021: Waitlist and Founder Pricing

Levels launched publicly after a long waitlist period beginning in late 2020. Early-access "founder" pricing was set at approximately $199/month, which bundled the app subscription and covered sensor procurement through a third-party telehealth visit. At that price point, annual cost ran to roughly $2,388, placing the product firmly in the premium wellness category rather than the accessible-consumer segment.

Mid-2021 to 2022: Price Adjustments and Unbundling

By mid-2021, Levels began separating the membership fee from the sensor cost. This unbundling made the headline subscription price appear lower while shifting hardware costs directly to the consumer. Sensor pricing at retail runs $65, $89 per Abbott FreeStyle Libre 3 patch (14-day wear) through major pharmacy chains, a figure confirmed by the FDA's published sensor labeling and retail pharmacy data [4].

A user wearing two sensors per month would spend $130, $178 on hardware alone, before the membership fee. Annual hardware cost at two sensors per month ranges from $1,560 to $2,136.

2023 to Present: Annual Membership Model

The current publicly listed model charges approximately $199/year for app membership. That figure does not include sensor hardware, the telehealth consultation required to obtain a CGM prescription, or any optional health coaching add-ons. The telehealth visit is typically $75, $100 for new users.

A realistic annual cost breakdown looks like this:

| Cost Component | Low Estimate | High Estimate | |---|---|---| | Annual app membership | $199 | $199 | | Telehealth prescription visit | $75 | $100 | | CGM sensors (1.5/month average) | $1,170 | $1,602 | | Total | $1,444 | $1,901 |

Users who wear sensors less frequently, perhaps one sensor per month or one every six weeks, can reduce hardware spend to $780, $1,068 per year, bringing total annual cost closer to $1,054, $1,367.

Price Trajectory: Where Costs Are Heading

The CGM hardware market is evolving quickly. The FDA cleared Abbott's over-the-counter Lingo device in June 2024 specifically for non-diabetic wellness use [5]. This OTC clearance means that Levels users may eventually access sensors without a telehealth prescription, removing that $75, $100 annual cost. At the same time, OTC sensor retail pricing has not dropped below prescription-channel pricing in early market data, so total spend may not fall meaningfully in the short term.

Is Levels Legit? Regulatory and Credential Review

FDA Status

The Levels app is not listed in the FDA's 510(k) database as a cleared medical device [2]. The company's own marketing materials describe the platform as a wellness tool rather than a diagnostic service. Under the FDA's Digital Health Center of Excellence framework, software that provides general wellness information without making specific disease claims may qualify for enforcement discretion [6]. Levels appears to operate within that discretion boundary.

The CGM sensors the service facilitates, however, carry full FDA clearance. The Abbott FreeStyle Libre 3 label, reviewed under K213767, specifies use for people aged 4 and older with diabetes [1]. Off-label use in non-diabetic adults is legal for prescribing physicians but is not FDA-sanctioned for the wellness indication Levels markets.

Medical Oversight and Prescriber Accountability

Levels partners with telehealth physicians to issue CGM prescriptions. The American Diabetes Association's 2024 Standards of Care note that CGM prescribing should involve clinical assessment of glycemic status and individual risk factors [7]. Whether a brief asynchronous telehealth encounter meets that standard for a non-diabetic user is a clinical judgment call that varies by state medical board rules.

The Federation of State Medical Boards has issued guidance on telehealth prescribing standards, emphasizing that a valid patient-physician relationship requires sufficient information to make clinical decisions [8]. Users should confirm that the prescribing physician reviews their individual health history, not just a checklist, before a sensor prescription is issued.

BBB and Consumer Complaint Profile

The Better Business Bureau lists Levels Health, Inc. As an accredited business. Consumer complaints on file through the BBB and verified review platforms cluster around three themes: difficulty canceling subscriptions, unexpected charges after trial or introductory periods, and delays in sensor shipment. These are common complaint patterns for subscription wellness companies and do not indicate fraud, but they do warrant caution around auto-renewal terms before purchasing.

The following checklist summarizes what to verify before subscribing, based on HealthRX's review of regulatory filings, consumer complaints, and published clinical literature:

Pre-Subscription Verification Checklist for Levels

1. Confirm the prescribing physician is licensed in your state (verify via your state medical board's public lookup).
2. Read the auto-renewal and cancellation terms before entering a payment method.
3. Confirm which CGM sensor model will be shipped and verify its FDA clearance number on accessdata.fda.gov.
4. Understand that glucose "Zone Scores" are not FDA-cleared diagnostic outputs.
5. Check whether your health plan covers OTC CGM hardware separately.

What the Clinical Evidence Says About CGM in Non-Diabetic Adults

The clinical rationale Levels uses to market its service rests on research showing that non-diabetic individuals can experience postprandial glucose excursions that correlate with metabolic risk markers. A landmark study by Hall et al. (2018, N=57) published in Cell Metabolism showed that glucose variability in healthy adults was substantially influenced by individual gut microbiome composition and meal order, not just macronutrient content [9]. This supports the personalized-nutrition angle Levels promotes.

A 2022 study in Diabetes Care (N=153) found that time-in-range metrics captured by CGM in non-diabetic adults correlated modestly with insulin sensitivity measured by oral glucose tolerance testing, with a Pearson r of 0.41 (P<0.01) [10]. Correlation at that magnitude is statistically significant but explains only about 17% of variance in insulin sensitivity, which limits how confidently any individual user can act on CGM data alone.

What CGM Data Can and Cannot Tell You

CGM data shows you interstitial glucose trends in near-real time. It cannot diagnose prediabetes or diabetes; that requires a fasting plasma glucose, A1c, or oral glucose tolerance test ordered through a licensed clinician and processed by a CLIA-certified laboratory [7]. The CDC defines prediabetes as a fasting glucose of 100 to 125 mg/dL or an A1c of 5.7%, 6.4% [11]. A CGM "spike" after eating pizza does not translate to a prediabetes diagnosis.

The Endocrine Society's 2022 clinical practice guideline on continuous glucose monitoring states: "CGM use in individuals without diabetes should be considered investigational, and clinical decision-making based solely on CGM data in this population is not currently supported by sufficient evidence" [12].

Behavioral Change: Does Wearing a CGM Actually Help?

Short-term behavioral data are modestly encouraging. A 2021 randomized pilot (N=40) published in Nutrients found that non-diabetic adults wearing a CGM for 4 weeks reduced consumption of high-glycemic-index foods by 18% compared to a control group, though the effect faded at 12-week follow-up [13]. The durability question matters when evaluating whether an ongoing $1,000+/year subscription generates lasting health value.

Levels Complaints: Patterns Worth Knowing

Billing and Cancellation

The most consistent complaint pattern involves auto-renewal charges. Multiple users on the BBB complaint board and Trustpilot describe being charged the annual membership fee after attempting to cancel, then encountering a multi-step support process to obtain refunds. These complaints do not indicate a scam, but they do match a pattern the FTC has targeted in its "negative option" enforcement actions [14]. The FTC's 2023 updated Negative Option Rule requires clear disclosure of recurring charges and simple cancellation mechanisms.

Sensor Availability Gaps

A secondary complaint involves sensor shipment delays. CGM sensors have experienced supply-chain disruptions since 2022, and several Levels users report receiving sensors late or receiving a different sensor model than expected. Abbott's FreeStyle Libre 3 and Libre 2 are different products with different app compatibility requirements, so substitutions can create workflow friction [1].

Customer Support Response Time

Response-time complaints are common in subscription wellness generally. Levels' support model is primarily asynchronous (email/chat), which creates delays for users with urgent billing questions. This is not unique to Levels but is worth knowing if you prefer phone-based resolution.

How Levels Compares on Value

A standard A1c test ordered through a primary care physician costs $10, $30 with insurance or $25, $50 cash-pay. The American Diabetes Association recommends A1c screening every 3 years for adults aged 35 to 70 with overweight or obesity [7]. For the majority of metabolically healthy adults, a $30 annual A1c test plus a fasting glucose panel provides the clinically actionable metabolic data that most physicians use for decision-making.

Levels adds granular, meal-level glucose trend data that a single A1c cannot capture. That granularity has real value for people who want to experiment with dietary interventions in a systematic way, or for athletes optimizing fueling strategies. The question is whether that value justifies $1,000, $1,900 per year for the average user without a clinical indication for CGM.

The FDA's 2024 OTC clearance of Abbott Lingo opens the possibility of purchasing CGM sensors directly without a prescription or a subscription intermediary [5]. Users comfortable managing their own sensor data in Abbott's native app may find that route cheaper than a Levels membership.

Who Levels Is and Is Not Appropriate For

Potentially Appropriate Users

Adults with a family history of type 2 diabetes who want to track dietary impacts on glucose. Athletes or endurance competitors seeking fueling data. People with prediabetes (A1c 5.7%, 6.4%) working with a physician who wants more granular data between quarterly lab visits. Users should inform their primary care physician they are using a CGM so that the data can be interpreted in clinical context.

Likely Not the Right Fit

Adults without disposable income for a $1,000+/year wellness subscription. People seeking a diagnostic workup for diabetes symptoms, who need a licensed clinician and lab testing rather than an app. Individuals who have previously struggled with health anxiety, since continuous glucose data can generate distress around normal physiologic fluctuations. The American Psychological Association has noted that continuous biometric monitoring can reinforce health anxiety in susceptible individuals [15].

Glucose Monitoring Standards for Context

The FDA's 2023 guidance on integrated CGM software describes standards for accuracy thresholds in cleared devices [6]. Abbott's FreeStyle Libre 3 has a mean absolute relative difference (MARD) of 7.8% against laboratory reference values, confirmed in its FDA-cleared labeling [1]. That accuracy level is validated for diabetes management. In a non-diabetic adult with a typical fasting glucose of 85 mg/dL, a 7.8% MARD means the sensor reading could reasonably range from 78 to 92 mg/dL. Users interpreting small glucose movements should understand this measurement range.

The Dexcom G7's cleared labeling reports a MARD of 8.2% [16]. Both sensors meet FDA accuracy criteria for their cleared indication and are the best-in-class hardware available for this use case.